期刊文献+

乳腺癌的内分泌治疗新进展 被引量:14

Endocrine Therapy of Breast Cancer
下载PDF
导出
摘要 乳腺癌是激素依赖性肿瘤,雌激素的长期刺激对乳腺癌的发生具有重要作用。对雌激素受体(ER)和(或)孕激素受体(PR)阳性的乳腺癌患者,术后都应该接受辅助内分泌治疗。应根据患者的具体情况个体化选用内分泌治疗方法,提高其作为乳腺癌术后辅助治疗和复发转移性乳腺癌解救治疗的疗效。本文将对绝经前、绝经后乳腺癌以及特殊情况下如复发转移性乳腺癌、男性乳腺癌的内分泌治疗进行综述,探讨内分泌治疗抵抗机制的最新进展。 Breast cancer is a hormone - dependent tumor in which oestrogen stimulus plays an important role in its oc- currence. For breast cancer patients whose ER and PR are positive, endocrine therapy should be adopted after opera- tion. Endocrine therapy should be applied in accordance with the patients' specific conditions to improve its efficacy as an adjuvant therapy and saving treatment for recurrent metastatic breast cancer. This paper summarizes the endocrine therapy for premenopausalbreast cancer, postmenopausal breast cancer and breast cancer in special cases like recurrent metastatic breast cancer and male breast cancer, and discusses the recent advances of resistance to endocrine therapy.
出处 《中国全科医学》 CAS CSCD 北大核心 2012年第9期959-962,共4页 Chinese General Practice
基金 国家自然科学基金资助项目(30900697) 江苏省"六大人才高峰"培养对象项目(2008060)
关键词 乳腺肿瘤 内分泌治疗 受体 雌激素 Breast neoplasms Endocrine therapy Receptor, estrogen
  • 相关文献

参考文献31

  • 1Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J].Breast Cancer,2007,(02):200-214.doi:10.2325/jbcs.954.
  • 2Dowsett M,Allred C,Knox J. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2(HER2) status with recurrence in the Arimidex,Tamoxifen,Alone or in Combination trial[J].Journal of Clinical Oncology,2008.1059-1065.
  • 3Legault C,Maki PM,Resnick SM. Effects of tamoxifen and raloxifene on memory and other cognitive abilities:cognition in the study of tamoxifen and raloxifene[J].Journal of Clinical Oncology,2009.5144-5152.
  • 4Cella D,Land S,Chang C-H. Symptom measurement in the Breast Cancer Prevention Trial(BCPT)(P-1):psychometric properties of a new measure of symptoms for midlife women[J].Breast Cancer Research and Treatment,2008.515-526.
  • 5Schilder CM,Seynaeve C,Beex LV. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer:results from the neuropsychological side study of the tamoxifen and exemestane adju-vant multinational trial[J].Journal of Clinical Oncology,2010.1294-1300.
  • 6Phillips K-A,Ribi K,Sun Z. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial[J].Breast,2010,(05):388-395.
  • 7Albain K,Barlow W,O′Malley F. Concurrent(CAFT) versus sequential(CAF-T) chemohormonal therapy(cyclophosphamide,doxorubicin,5-fluorouracil,tamoxifen) versus T alone for postmenopausal,node-positive,estrogen(ER) and/or progesterone(PgR) receptor-positive breast cancer:mature outcomes and new biologic correlates on phase Ⅲ intergroup trial 0100(SWOG-8814)[J].Breast Cancer Research and Treatment,2004,(Suppl 1):A-37.
  • 8Ejlertsen B,Dombernowski P,Mouridsen HT. Comparable effect of ovarian ablation(OA) and CMF chemotherapy in pre-menopausal hormone receptor positive breast cancer patients(PRP)[J].Proceedings of American Society of Clinical Oncology,1999.66a.
  • 9Ochsenkühn R,Hermelink K,Clayton AH. Menopausal status in breast cancer patients with past chemotherapy determines long-term hypoactive sexual desire disorder[J].JOURNAL OF SEXUAL MEDICINE,2011,(05):1486-1494.
  • 10Kaufmann M,Jonat W,Blamey R. Survival analysis from the ZEBRA study:goserelin(Zoladex) versus CMF in premenopausal women with node-positive breast cancer[J].European Journal of Cancer,2003,(12):1711-1717.

同被引文献162

引证文献14

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部